US Rx Drug Prices Up 2.3% In 2nd-Qtr 1997

3 September 1997

US prescription drug prices increased 2.3% in 1997's second quarterover second-quarter 1996, the same rise as that reported for prescription drugs in first-quarter 1997, according to IMS America's Quarterly Pricing Report.

The growth rate continues to be in line with the US government's price indexes. As measured by the Bureau of Labor Statistics, the Consumer Price Index for all items for June 1997 was also 2.3%, while the industry-weighted Producer Price Index was 2.7%.

The 2.3% second-quarter rise reflects a slight reduction in the 1997 inflation rate for branded drug products and a slower deflation rate for generics, according to IMS. Overall prices of branded products were up 3.4% during the period, while brand prices rose 3.8%. Prices of generics in the overall market fell 8.8% compared to those in second-quarter 1996, representing the lowest and first single-digit quarterly rate decrease in prices for generics in almost two years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight